Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.35 |
| ▸ | NOS3 | P29474 | 3/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707782 | 0.79 | NOS1 (0.47) | NOS1NOS3 | |
| SCHEMBL6694500 | 0.68 | NOS1 (0.43) | NOS1NOS2NOS3 | |
| SCHEMBL6699066 | 0.65 | NOS3 (0.31) | NOS1NOS2NOS3 | |
| SCHEMBL6699070 | 0.63 | NOS1 (0.41) | NOS1NOS3 | |
| SCHEMBL3366206 | 0.61 | ASIC3 (0.53) | NOS1NOS2NOS3 | |
| SCHEMBL6707783 | 0.60 | NOS3 (0.35) | NOS1NOS2NOS3 | |
| SCHEMBL6630681 | 0.59 | NOS1 (0.52) | NOS1NOS3 | |
| SCHEMBL6632307 | 0.58 | NOS1 (0.60) | NOS1NOS3 | |
| SCHEMBL6618736 | 0.58 | NOS1 (0.64) | NOS1NOS3 | |
| SCHEMBL15777763 | 0.58 | KDM1A (0.69) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| EP-0946512-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER (US) | 2003-10-08 | — | — | EP | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| US-20040142924-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | PFIZER INC | 2004-07-22 | — | — | US | disclosed |
| EP-0946512-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20020103227-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | LOWE JOHN A (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | LOWE JOHN A (US) | 2002-03-14 | — | — | US | disclosed |
| US-6235750-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | NOS1 1/4885NOS2 2/4885NOS3 3/4885 |
| US-20040142924-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | NOS1 1/4885NOS2 2/4885NOS3 3/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | NOS1 1/4885NOS2 6/4885NOS3 2/4885 |
| US-20020103227-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | NOS1 1/4885NOS2 2/4885NOS3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.